Abstract

ObjectiveIntestinal barrier function is vital for homeostasis. Conditions where the mucosal barrier is compromised lead to increased plasma content of lipopolysaccharide (LPS). LPS acts on Toll-like receptor 4 (TLR4) and initiates cellular inflammatory responses. TLR4 receptors have been identified on enteric neurons and LPS exposure causes neuronal loss, counteracted by vasoactive intestinal peptide (VIP), by unknown mechanisms. In addition AMP activated protein kinase (AMPK) stimulation causes loss of enteric neurons. This study investigated a possible role of AMPK activation in LPS-induced neuronal loss.DesignPrimary cultures of myenteric neurons isolated from rat small intestine were used. Cultures were treated with LPS (0.2–20 µg/mL) with and without TAK1-inhibitor (5Z)-7-Oxozeaenol (10−6 M) or AMPK inhibitor compound C (10−5 M). AMPK-induced neuronal loss was verified treating cultures with three different AMPK activators, AICAR (10−4−3×10−3 M), metformin (0.2–20 µg/mL) and A-769662 (10−5−3×10−4 M) with or without the presence of compound C (10−5 M). Upstream activation of AMPK-induced neuronal loss was tested by treating cultures with AICAR (10−3 M) in the presence of TAK1 inhibitor (5Z)-7-Oxozeaenol (10−6 M). Neuronal survival and relative numbers of neurons immunoreactive (IR) for VIP were evaluated using immunocytochemistry.ResultsLPS caused a concentration dependent loss of neurons. All AMPK activators induced loss of myenteric neurons in a concentration dependent manner. LPS-, AICAR- and metformin-,but not A-769662-, induced neuronal losses were inhibited by presence of compound C. LPS, AICAR or metformin exposure increased the relative number of VIP-IR neurons; co-treatment with (5Z)-7-Oxozeaenol or compound C reversed the relative increase in VIP-IR neurons induced by LPS. (5Z)-7-Oxozeaenol, compound C or A-769662 did not per se change neuronal survival or relative numbers of VIP-IR neurons.ConclusionAMPK activation mimics LPS-induced loss of cultured myenteric neurons and LPS-induced neuronal loss is counteracted by TAK1 and AMPK inhibition. This suggests enteric neuroimmune interactions involving AMPK regulation.

Highlights

  • The gastrointestinal (GI) tract comprises the body’s largest surface to the outside environment

  • AMPK activation mimics LPS-induced loss of cultured myenteric neurons and LPS-induced neuronal loss is counteracted by transforming growth factor-b-activated kinase 1 (TAK1) and AMPK inhibition

  • Current study re-affirmed previous findings showing that Escherichia coli derived LPS induces neuronal loss in primary cultures of adult myenteric neurons. [8, 9] The novel findings presented here are that presence of the AMPK inhibitor compound C protects myenteric neurons against LPS-induced neuronal loss and that, by using three independent AMPK activators, AMPK activation was found to mimic LPS exposure in that it induced loss of cultured myenteric neurons

Read more

Summary

Introduction

The gastrointestinal (GI) tract comprises the body’s largest surface to the outside environment. It is vital for nutrient uptake and contains the human microbiome, consisting of more than 100 trillion microorganisms with different properties. [8, 9] vasoactive intestinal peptide (VIP) has been highlighted as being protective in the response to LPS mediated TLR4 activation. LPS exposure in vitro has previously been shown to cause loss of porcine and rat enteric neurons, probably through TLR4 activation since this receptors is expressed on a subpopulation of enteric neurons. It reduces LPS-induced inflammation and enteric neuronal loss. It reduces LPS-induced inflammation and enteric neuronal loss. [9, 10]

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call